RESUMEN
Rapid neurotransmission is mediated through a superfamily of Cys-loop receptors that includes the nicotinic acetylcholine (nAChR), gamma-aminobutyric acid (GABA(A)), serotonin (5-HT(3)) and glycine receptors. A class of ligands, including galanthamine, local anesthetics and certain toxins, interact with nAChRs non-competitively. Suggested modes of action include blockade of the ion channel, modulation from undefined extracellular sites, stabilization of desensitized states, and association with annular or boundary lipid. Alignment of mammalian Cys-loop receptors shows aromatic residues, found in the acetylcholine or ligand-binding pocket of nAChRs, are conserved in all subunit interfaces of neuronal nAChRs, including those that are not formed by alpha subunits on the principal side of the transmitter binding site. The amino-terminal domain containing the ligand recognition site is homologous to the soluble acetylcholine-binding protein (AChBP) from mollusks, an established structural and functional surrogate. We assess ligand specificity and employ X-ray crystallography with AChBP to demonstrate ligand interactions at subunit interfaces lacking vicinal cysteines (i.e. the non-alpha subunit interfaces in nAChRs). Non-competitive nicotinic ligands bind AChBP with high affinity (K(d) 0.015-6 microM). We mutated the vicinal cysteine residues in loop C of AChBP to mimic the non-alpha subunit interfaces of neuronal nAChRs and other Cys loop receptors. Classical nicotinic agonists show a 10-40-fold reduction in binding affinity, whereas binding of ligands known to be non-competitive are not affected. X-ray structures of cocaine and galanthamine bound to AChBP (1.8 A and 2.9 A resolution, respectively) reveal interactions deep within the subunit interface and the absence of a contact surface with the tip of loop C. Hence, in addition to channel blocking, non-competitive interactions with heteromeric neuronal nAChR appear to occur at the non-alpha subunit interface, a site presumed to be similar to that of modulating benzodiazepines on GABA(A) receptors.
Asunto(s)
Proteínas Portadoras/química , Proteínas Portadoras/metabolismo , Galantamina , Parasimpaticomiméticos , Receptores Nicotínicos/química , Receptores Nicotínicos/metabolismo , Secuencia de Aminoácidos , Animales , Aplysia , Sitios de Unión , Proteínas Portadoras/genética , Cocaína/química , Cocaína/metabolismo , Cristalografía por Rayos X , Galantamina/química , Galantamina/metabolismo , Humanos , Modelos Moleculares , Datos de Secuencia Molecular , Neuronas/metabolismo , Parasimpaticomiméticos/química , Parasimpaticomiméticos/metabolismo , Estructura Cuaternaria de Proteína , Subunidades de Proteína/química , Subunidades de Proteína/genética , Subunidades de Proteína/metabolismo , Ensayo de Unión Radioligante , Receptores Nicotínicos/genética , Alineación de Secuencia , Vasoconstrictores/química , Vasoconstrictores/metabolismoRESUMEN
The paper begins with a discussion of the goals of metabolic predictions in early drug research, and some difficulties toward this objective, mainly the various substrate and product selectivities characteristic of drug metabolism. The major in silico approaches to predict drug metabolism are then classified and summarized. A discrimination is, thus, made between 'local' and 'global' systems. In its second part, an evaluation of METEOR, a rule-based expert system used to predict the metabolism of drugs and other xenobiotics, is reported. The published metabolic data of ten substrates were used in this evaluation, the overall results being discussed in terms of correct vs. disputable (i.e., false-positive and false-negative) predictions. The predictions for four representative substrates are presented in detail (Figs. 1-4), illustrating the interest of such an evaluation in identifying where and how predictive rules can be improved.
Asunto(s)
Sistemas Especialistas , Galantamina/metabolismo , Indinavir/metabolismo , Piridinas/metabolismo , Tiazepinas/metabolismo , Tramadol/metabolismo , Analgésicos Opioides/metabolismo , Fármacos Cardiovasculares/metabolismo , Simulación por Computador , Inhibidores de la Proteasa del VIH/metabolismo , Humanos , Estructura Molecular , Parasimpaticomiméticos/metabolismo , Programas InformáticosRESUMEN
Acetylcholine outflow can be modulated through inhibitory presynaptic muscarinic autoreceptors. This study was to identify which subtype is involved in mouse cortex. Five muscarinic antagonists and their ability to elevate stimulation-induced (S-I) acetylcholine outflow were tested in the presence of neostigmine, which decreased S-I outflow. The potency of each antagonist was determined, expressed as a ratio of the potency of each other antagonist and compared with the potency ratios of the antagonists for each of the defined muscarinic receptors (M(1)-M(4)), as recorded in the literature. Linear regression analysis revealed that the data fitted the M(2) (r(2)>0.97) and M(4) (r(2)>0.85) subtypes best, with no correlation for the M(1) and M(3) subtypes.
Asunto(s)
Acetilcolina/metabolismo , Corteza Cerebral/metabolismo , Receptores Muscarínicos/metabolismo , Alcaloides/metabolismo , Alcaloides/farmacología , Animales , Atropina/metabolismo , Atropina/farmacología , Autorreceptores/metabolismo , Unión Competitiva/fisiología , Furanos , Masculino , Ratones , Antagonistas Muscarínicos/metabolismo , Antagonistas Muscarínicos/farmacología , Naftalenos , Neostigmina/metabolismo , Neostigmina/farmacología , Parasimpatolíticos/metabolismo , Parasimpatolíticos/farmacología , Parasimpaticomiméticos/metabolismo , Parasimpaticomiméticos/farmacología , Piperidinas/metabolismo , Piperidinas/farmacología , Pirenzepina/análogos & derivados , Pirenzepina/metabolismo , Pirenzepina/farmacología , Receptor Muscarínico M2 , Receptor Muscarínico M4RESUMEN
The interaction of (R) and (S) enantiomers of the chiral oxotremorine analogue BM-5 with muscarinic acetylcholine receptors was studied in vitro using radioligand binding and isolated tissue preparations. The in vivo effects of (R)-BM-5 were also studied in anaesthetised cat. No receptor or tissue selectivity was found for either enantiomer in radioligand binding studies in cells expressing human muscarinic receptors (M1-M5) or in guinea pig tissues. The affinity of (R)-BM-5 was about 40 times, or 15-60 times higher than that of (S)-BM-5 in recombinant cells or in guinea pig tissues, respectively. Both enantiomers induced contraction of the guinea pig isolated urinary bladder and ileum. (R)-BM-5 was more potent than (S)-BM-5 in bladder (EC50 590 and 3500 nM, respectively) and in ileum (EC50 39 and 2600 nM, respectively). The maximal agonist effect was lower for (R)-BM-5 than for (S)-BM-5 in bladder (2.7% and 6.6%, respectively) and in ileum (32% and 48%, respectively). Contractions were completely inhibited by atropine (1 microM). In vivo, (R)-BM-5 induced bladder contraction and salivation after intravenous administration in the anaesthetised cat (ED50 4.1 and 6.2 microg kg(-1), respectively). In conclusion, (R)- and (S)-BM-5 act as partial muscarinic agonists in the isolated bladder and ileum. (R)-BM-5 was the more potent enantiomer but had a lower maximal agonist effect giving an opposed enantioselectivity for affinity and efficacy. (R)-BM-5 showed agonist activity in vivo, confirming in vitro findings. From affinity and efficacy data it can be concluded that the effects of racemic BM-5 are mediated by the (R)-enantiomer.
Asunto(s)
Agonistas Muscarínicos/farmacología , Pirrolidinas/farmacología , Animales , Unión Competitiva , Células CHO , Gatos , Cricetinae , Relación Dosis-Respuesta a Droga , Cobayas , Humanos , Íleon/efectos de los fármacos , Íleon/metabolismo , Íleon/fisiología , Técnicas In Vitro , Cinética , Masculino , Agonistas Muscarínicos/metabolismo , Antagonistas Muscarínicos/farmacología , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Parasimpaticomiméticos/metabolismo , Parasimpaticomiméticos/farmacología , Pirrolidinas/metabolismo , Quinuclidinil Bencilato/antagonistas & inhibidores , Quinuclidinil Bencilato/metabolismo , Quinuclidinil Bencilato/farmacología , Ensayo de Unión Radioligante , Receptores Muscarínicos/clasificación , Receptores Muscarínicos/metabolismo , Estereoisomerismo , Tritio , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria/metabolismo , Vejiga Urinaria/fisiologíaRESUMEN
Quantification of human brain muscarinic cholinergic receptors was investigated with the use of [11C]N-methyl-4-piperidyl benzylate (NMPB) and positron emission tomography (PET). Whole-brain uptake of NMPB at 90 to 110 minutes after intravenous injection was approximately 10% of the administered dose. The initial cerebral distribution of NMPB corresponded to the pattern of cerebral perfusion; however, at progressively longer postinjection intervals, regional distinctions consistent with muscarinic receptor binding were evident: activity at 90 to 110 minutes postinjection was highest in the striatum and cerebral cortex, intermediate in the thalamus and pons, and lowest in the cerebellum. After the development of a chromatographic system for isolation of authentic [11C]NMPB in plasma, tracer kinetic modeling was used to estimate receptor binding from the cerebral and arterial plasma tracer time-courses. Ligand transport rate and receptor-binding estimates were obtained with the use of compartmental models and analytical methods of varying complexity, including a two-parameter pixel-by-pixel-weighted integral approach and regional least-squares curve-fitting analyses employing both two- and three-compartment model configurations. In test-retest experiments, precision of the methods and their abilities to distinguish altered ligand delivery from binding in occipital cortex during an audiovisual presentation were evaluated. Visual stimulation increased the occipital blood-to-brain NMPB transport rate by 25% to 46% in estimates arising from the various approaches. Weighted integral analyses resulted in lowest apparent transport changes and in a concomitant trend toward apparent binding increases during visual activation. The regional least-squares procedures were superior to the pixel-by-pixel method in isolating the effects of altered tracer delivery from receptor-binding estimates, indicating larger transport effects and unaltered binding. Precision was best (less than 10% test-retest differences) for the weighted integral analyses and was somewhat lower in the least-squares analyses (10-25% differences). The authors conclude that pixel-by-pixel-weighted integral analyses of NMPB distribution introduce transport biases into receptor-binding estimates. Similar confounding effects also are predicted in noncompartmental analyses of delayed radiotracer distribution. The use of regional nonlinear least-squares fitting to two- and three-compartment models, although more labor intensive, provides accurate distinction of receptor-binding estimates from tracer delivery with acceptable precision in both intra- and intersubject comparisons.
Asunto(s)
Bencilatos/metabolismo , Encéfalo/metabolismo , Parasimpaticomiméticos/metabolismo , Piperidinas/metabolismo , Receptores Muscarínicos/análisis , Tomografía Computarizada de Emisión , Adulto , Transporte Biológico , Radioisótopos de Carbono , Femenino , Humanos , Masculino , Lóbulo Occipital/metabolismo , Receptores Muscarínicos/metabolismo , Sensibilidad y Especificidad , Distribución TisularRESUMEN
The influence of drugs affecting different neurotransmitter systems on an acute abstinence heanshaking (AHS) model induced by nalorphine or naloxone was studied in 9-day-old rat pups pretreated (3 h before) with morphine (10mg/kg, i.p.). One hour after the injection of nalorphine (10 mg/kg, i.p.) AHS was stopped by a second dose of morphine (10 mg/kg, i.p.) and reinitiated 1 h later by a higher dose of nalorphine (20 mg/kg, i.p.). In other groups AHS was blocked by spiroperidol (0.1 mg/kg, i.p.), clonidine (0.01 mg/kg, i.p.) or scopolamine (50 mg/kg, i.p.). In these groups a second injection of nalorphine did not reinitiate AHS. In dose-effect curve experiments the AHS induced by naloxone or nalorphine was significantly reduced by previous injections of scopolamine, spiroperidol, metergoline or phentolamine in the corresponding groups. Scopolamine was the only antagonist which displaced the AHS dose-effect curves to the right without affecting the maximal response. Since no common receptors exist for a direct competitive interaction between opiate antagonists and scopolamine, these experiments suggest that a direct molecular relationship exists between the tissue concentration of nalorphine (or naloxone) and the endogenous ACh release during abstinence. Thus, the AHS model in 9-day-old rats clearly differentiates specific from non-specific blockade of the abstinence syndrome, and confirms a distinct or primary role of cholinergic neurotransmission in morphine abstinence
Asunto(s)
Ratas , Animales , Dependencia de Morfina/sangre , Morfina/antagonistas & inhibidores , Neurotransmisores/fisiología , Parasimpaticomiméticos/metabolismo , Ratas Wistar/fisiología , EscopolaminaRESUMEN
1. We have shown earlier that pilocarpine strongly inhibits mouse and human liver coumarin 7-hydroxylase activity of CYP 2A and pentoxyresorufin O-deethylase activity of CYP 2B in vitro. Since pilocarpine, like coumarin, contains a lactone structure we have studied in more detail its inhibitory potency on mouse and human liver coumarin 7-hydroxylation. 2. Pilocarpine was a competitive inhibitor of coumarin 7-hydroxylase in vitro both in mouse and human liver microsomes although it was not a substrate for CYP 2A5. Ki values were similar, 0.52 +/- 0.22 microM in mice and 1.21 +/- 0.51 microM in human liver microsomes. 3. Pilocarpine induced a type II difference spectrum in mouse, human and recombinant CYP 2A5 yeast cell microsomes, with Ka values of 3.7 +/- 1.6, 1.6 +/- 1.1 and 1.5 +/- 0.1 microM, respectively. 4. Increase in pH of the incubation medium from pH 6 to 7.5 increased the potency of inhibition of coumarin 7-hydroxylation by pilocarpine. 5. Superimposition of pilocarpine and coumarin in such a way that their carbonyls, ring oxygens and the H-7' of coumarin and N-3 of pilocarpine overlap yielded a common molecular volume of 82%. 6. The results indicate that pilocarpine is a competitive inhibitor and has a high affinity for mouse CYP 2A5 and human CYP 2A6. In addition the immunotype nitrogen of pilocarpine is coordinated towards the haem iron in these P450s.
Asunto(s)
Hidrocarburo de Aril Hidroxilasas , Cumarinas/metabolismo , Inhibidores Enzimáticos del Citocromo P-450 , Inhibidores Enzimáticos/farmacología , Oxigenasas de Función Mixta/antagonistas & inhibidores , Parasimpaticomiméticos/farmacología , Pilocarpina/farmacología , Animales , Sitios de Unión , Unión Competitiva , Citocromo P-450 CYP2A6 , Sistema Enzimático del Citocromo P-450/metabolismo , Femenino , Humanos , Hidroxilación/efectos de los fármacos , Cinética , Masculino , Ratones , Ratones Endogámicos DBA , Microsomas Hepáticos/enzimología , Oxigenasas de Función Mixta/metabolismo , Modelos Químicos , Parasimpaticomiméticos/metabolismo , Pilocarpina/metabolismoRESUMEN
The rationale for the use of muscarinic antagonists in bronchopulmonary dysplasia (BPD) is based on the physiology and pharmacology of airway smooth muscle, the pathology of BPD, and the response of infants with BPD to bronchodilators, in vivo and in vitro studies of airway smooth muscle of newborn animals and humans indicate that vagal efferent airway innervation and/or muscarinic receptors are functional at birth, as well as early in gestation. Current concepts regarding muscarinic receptor subtypes suggest that M3 receptors mediate airway smooth muscle contraction, M2 receptors are autoinhibitory and limit vagally-mediated bronchoconstriction, and M1 receptors may play a facilitatory role in ganglionic transmission. Muscarinic receptor subtypes appear to be functionally expressed at birth but may undergo developmental regulation. Infants with BPD have an elevated pulmonary resistance that is accompanied by hypertrophy of airway smooth muscle, b2-agonists cause bronchodilation in BPD as does atropine in infants recovering from severe BPD. The synthetic congener of atropine, ipratropium bromide (IPB) causes bronchodilation in ventilator-dependent infants with BPD in a dose-dependent fashion. Nebulized IPB causes a decrease in respiratory resistance that reaches a maximum of 20% at 175 mg. The bronchodilation seen with muscarinic antagonists suggests that part of the elevated resistance associated with BPD is due to increased muscarinic tone, presumably vagal in origin. When IPB is combined with salbutamol (0.04 mg) the response is increased in magnitude and duration; reaching a slightly larger decreases in resistance (26%) that is now accompanied by an increase in compliance (20%).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Displasia Broncopulmonar/metabolismo , Parasimpaticomiméticos/antagonistas & inhibidores , Parasimpaticomiméticos/metabolismo , Animales , Broncodilatadores/uso terapéutico , Displasia Broncopulmonar/tratamiento farmacológico , Esquema de Medicación , Humanos , Recién Nacido , Ipratropio/administración & dosificación , Ipratropio/uso terapéutico , Músculo Liso/metabolismo , Parasimpaticomiméticos/uso terapéutico , Sistema Respiratorio/metabolismoRESUMEN
Ligand binding properties of membrane-bound and solubilized muscarinic acetylcholine receptor (mAChR) subtypes (human m1 and m2; rat m3 and m4), produced by using a baculovirus infection system in Sf9 insect cells have been studied. Most of the studied ligands that have been proposed previously to be selective for some subtype had similar selectivity to mAChRs in Sf9 cell membranes. Only tropicamide, which has been proposed as m4-specific ligand, had higher affinity for m1. Solubilization of receptors decreased binding affinities of all studied ligands to m1 and m3 mAChR, on average 10- and 75-fold, respectively. The solubilization of m2 mAChR had only slight influence on the affinity of subtype nonspecific ligands, but decreased 5- to 10-fold the affinities of m2-specific ligands and increased up to 6-fold the affinities of m1- and m3-specific ligands. Effects of m4 mAChR were similar to those on m2, but without a decrease in affinities of m2-specific ligands. This combination of reduction and increase of binding affinities caused by solubilization led to loss of subtype selectivity of most ligands studied. Only AF-DX 116 [11-((2-[(diethylamino)-methyl]-1- piperidinyl)-acetyl)-5,11-dihydro-6H-pyrido(2,3b)-(1,4)-benzodiazepin -6-ontelenzepine] and gallamine retained their selectivity for m2 after solubilization of mAChR. Incorporation of mAChR into brain membranes restored their subtype specificity in ligand binding. These data suggest that subtype-specific antagonist binding to mAChR is generally modulated by the lipid environment of receptor protein.
Asunto(s)
Receptores Muscarínicos/metabolismo , Animales , Baculoviridae , Membrana Celular/metabolismo , Ácidos Cólicos/química , Digitonina/química , Humanos , Técnicas In Vitro , Ligandos , Lípidos de la Membrana/química , Mariposas Nocturnas , Parasimpatolíticos/metabolismo , Parasimpaticomiméticos/metabolismo , Ratas , Receptores Muscarínicos/química , Receptores Muscarínicos/clasificación , Proteínas Recombinantes , Solubilidad , Relación Estructura-ActividadRESUMEN
The binding of L-[benzilic-4,4'-3H]quinuclidinyl benzilate was studied in the plasma membrane fraction of bovine tracheal smooth muscle treated with the alkylating agent N-ethylmaleimide (NEM). It was found that NEM (2.5 mM) reduced significantly the Bmax from 1116 to 853 fmol/mg protein and increased the KD values of the muscarinic acetylcholine receptor (mAchR) activity from 36 to 61 pM. The mAchR subtypes in these plasma membranes were studied using competition experiments with selective antagonists. Pirenzepine displayed low competitive activity, having a pKi of 6.91 +/- 0.03, which was similar to that of AF-DX 116 (11[[2-[(diethylamino)methyl]- 1-piperidinyl]-acetyl]-5,11-dihydro-6H-pyrido[2,3- b][1,4]benzodiazepine-6-one); (pKi = 6.90 +/- 0.04), whereas hexahydrodifenidol (HDD) and its p-fluoro-derivative (p-FHHSiD) showed higher affinities than pirenzepine, having pKi values of 7.45 +/- 0.05 and 7.17 +/- 0.06, respectively. The antagonist 4-diphenylacetoxy-N-methylpiperidine methobromide (4-DAMP) showed a pKi of 8.25 +/- 0.03, which did not differ significantly from the affinity shown by methoctramine (pKi = 8.00 +/- 0.04). These data indicate that the mAchR associated with the plasma membrane fraction isolated from bovine airway smooth muscle can be classified as an M2 subtype muscarinic receptor. NEM treatment altered the affinities of the mAchR towards specific antagonists, such as methoctramine (Ki increased 3 times), and the results indicated that the alkylated mAchR behaves as a chemically modified M2 subtype. This suggests the presence of thiol groups controlling the antagonist binding activity of this muscarinic receptor subtype.
Asunto(s)
Diaminas/metabolismo , Músculo Liso/metabolismo , Parasimpaticomiméticos/metabolismo , Receptores Muscarínicos/metabolismo , Tráquea/metabolismo , Alquilación , Animales , Sitios de Unión , Bovinos , Etilmaleimida/farmacología , Técnicas In Vitro , Quinuclidinil Bencilato/metabolismoRESUMEN
A diversity of nicotinic acetylcholine receptor (nAChR) subtypes has been identified in mammalian brain using recombinant DNA technology. Alterations in the activity of these acetylcholinegated ion channels have been implicated in a number of central nervous system disorders including Alzheimer's disease (AD). The potential therapeutic usefulness of (-)-nicotine [(S)-3-(1-methyl-2-pyrrolidinyl) pyridine], the prototypic agonist at nAChRs, is severely limited by side effects that are the result of activation of both cholinergic and noncholinergic pathways in the central and peripheral nervous systems. This study sought to determine the in vitro selectivity of (S)-3-methyl-5-(1methyl-2-pyrrolidinyl)isoxazole (ABT 418), a novel analog of (-)-nicotine in which the pyridine ring was replaced with an isoxazole bioisotere, to activate nAChRs. ABT 418 was a potent inhibitor of [3H]-cytisine binding to nAChR in rat brain (Ki = 3 nM) but was inactive (Ki > 10,000 nM) in 37 other receptor/neurotransmitter-uptake/enzyme/transduction system binding assays, including those for alpha-bungarotoxin, muscarinic and 5-hydroxytryptamine3 receptors. In PC12 cells, patch-clamp studies indicated that ABT 418 was an agonist with an EC50 value of 209 microM, a potency to activate cholinergic channel currents some 4-fold less than that of (-)-nicotine (52 microM). Channel current responses elicited by ABT 418 were prevented by the cholinergic channel blocker, mecamylamine. ABT 418 was also approximately 10-fold less potent (EC50 value = 380 nM) than (-)-nicotine (40 nM) in increasing [3H]-dopamine release from rat striatal slices, an effect that was blocked by the nAChR antagonist, dihydro-beta-erythroidine (10 microM).2+ In contrast, ABT 418 appeared equipotent with (-)-nicotine in enhancing 86Rb+ flux from mouse thalamic synaptosomes. ABT 418 demonstrated an in vitro pharmacological profile of cholinergic channel activation that was robust at some nAChR, but not others. The reasons for this are unclear. However, a nAChR subtype selectivity may account for the in vitro potency differences of ABT 418 on various neurotransmitter systems, and the substantial separation between the cognitive enhancement/anxiolytic benefits, and the reduced central nervous system side-effect liabilities seen in vivo. ABT 418 represents the first neuronal nAChR ligand that differentiates the toxicities/liabilities and other negative aspects normally associated with liabilities and other negative aspects normally associated with (-)-nicotine from the potential pharmacological benefits of selective cholinergic channel activation.
Asunto(s)
Ansiolíticos/farmacología , Cognición/efectos de los fármacos , Canales Iónicos/efectos de los fármacos , Isoxazoles/farmacología , Parasimpaticomiméticos/metabolismo , Pirrolidinas/farmacología , Alcaloides/metabolismo , Animales , Azocinas , Unión Competitiva , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Dopamina/metabolismo , Canales Iónicos/fisiología , Isoxazoles/metabolismo , Cinética , Masculino , Ratones , Nicotina/metabolismo , Células PC12 , Pirrolidinas/metabolismo , Quinolizinas , Ratas , Ratas Sprague-Dawley , Receptores Colinérgicos/efectos de los fármacos , Receptores Colinérgicos/metabolismo , Receptores Nicotínicos/efectos de los fármacos , Receptores Nicotínicos/metabolismo , Rubidio/farmacocinética , Radioisótopos de Rubidio , TritioRESUMEN
Xanomeline [3(3-hexyloxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1- methylpyridine] has been evaluated as a muscarinic receptor agonist. In vitro, xanomeline had high affinity for muscarinic receptors in brain homogenates, but had substantially less or no affinity for a number of other neurotransmitter receptors and uptake sites. In cells stably expressing genetic m1 receptors, xanomeline increased phospholipid hydrolysis in CHO, BHK and A9 L cells to 100, 72 and 55% of the nonselective agonist carbachol. In isolated tissues, xanomeline had high affinity for M1 receptors in the rabbit vas deferens (IC50 = 0.006 nM), low affinity for M2 receptors in guinea pig atria (EC50 = 3 microM), was a weak partial agonist in guinea pig ileum and was neither an agonist nor antagonist in guinea pig bladder. In vivo, xanomeline increased striatal levels of dopamine metabolites, presumably by acting at M1 heteroreceptors on dopamine neurons to increase dopamine release. In contrast, xanomeline had only a relatively small effect on acetylcholine levels in brain, indicating that it is devoid of actions at muscarinic autoreceptors. In the gastrointestinal tract, xanomeline inhibited small intestinal and colonic motility, but increased small intestinal transmural potential difference. In contrast to the nonselective muscarinic agonist oxotremorine, xanomeline did not produce salivation, tremor nor hypothermia; it did, however, increase heart rate. The present data are consistent with the interpretation that xanomeline is a novel muscarinic receptor agonist with functional selectivity for M1 muscarinic receptors both in vitro and in vivo.
Asunto(s)
Parasimpaticomiméticos/farmacología , Piridinas/farmacología , Receptores Muscarínicos/fisiología , Tiadiazoles/farmacología , Animales , Temperatura Corporal/efectos de los fármacos , Células CHO , Cricetinae , Depresión Química , Motilidad Gastrointestinal/efectos de los fármacos , Cobayas , Atrios Cardíacos/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hidrólisis , Íleon/efectos de los fármacos , Técnicas In Vitro , Fosfatos de Inositol/metabolismo , Masculino , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Contracción Miocárdica/efectos de los fármacos , Neurotransmisores/metabolismo , Parasimpaticomiméticos/metabolismo , Conejos , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Receptores Muscarínicos/efectos de los fármacos , Receptores Muscarínicos/metabolismo , Receptores de Neurotransmisores/efectos de los fármacos , Salivación/efectos de los fármacos , Transfección , Temblor/inducido químicamente , Vejiga Urinaria/efectos de los fármacos , Conducto Deferente/efectos de los fármacosRESUMEN
Xanomeline [3(3-hexyloxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-me thylpyridine)] was evaluated in vivo in rat brain for effects on neurotransmitter turnover and inhibition of ex vivo binding of muscarinic radioligands. Xanomeline produced dose-related increases in the metabolite of dopamine, dihydroxyphenylacetic acid (DOPAC), in striatum. The increases in striatal DOPAC levels produced by xanomeline were antagonized by the relatively selective M1 antagonist trihexyphenidyl, suggesting that xanomeline interacts with M1 heteroreceptors on dopamine nerve terminals. Xanomeline produced small increases in striatal acetylcholine levels and did not antagonize the large increases in acetylcholine produced by the nonselective muscarinic agonist oxotremorine, indicating that xanomeline did not block M2 autoreceptors. Xanomeline inhibited ex vivo binding of muscarinic radioligands to homogenates of brain and the inhibition of ex vivo binding occurred in the same dose range as increases in DOPAC levels. Xanomeline did not appreciably induce salivation or antagonize oxotremorine-induced salivation indicating that xanomeline does not interact with M3 receptors. The effects of xanomeline on ex vivo binding and DOPAC levels lasted for about 3 hr and were evident after oral administration. An analog of xanomeline with similar in vivo effects did not inhibit acetylcholinesterase or choline acetyltransferase and inhibited choline uptake only at concentrations much higher than those required to inhibit binding. These data indicate xanomeline is selective agonist for M1 over M2 and M3 receptors in vivo in rat. It is not known whether xanomeline interacts with m4 or m5 receptors in vivo.
Asunto(s)
Encéfalo/efectos de los fármacos , Parasimpaticomiméticos/farmacología , Psicotrópicos/farmacología , Piridinas/farmacología , Receptores Muscarínicos/fisiología , Tiadiazoles/farmacología , Ácido 3,4-Dihidroxifenilacético/metabolismo , Acetilcolina/metabolismo , Acetilcolinesterasa/metabolismo , Administración Oral , Animales , Disponibilidad Biológica , Encéfalo/enzimología , Encéfalo/metabolismo , Colina/farmacocinética , Colina O-Acetiltransferasa/metabolismo , Inhibidores de la Colinesterasa/farmacología , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Masculino , Neurotransmisores/metabolismo , Inhibidores de la Captación de Neurotransmisores/farmacología , Parasimpaticomiméticos/metabolismo , Psicotrópicos/farmacocinética , Piridinas/farmacocinética , Ratas , Ratas Sprague-Dawley , Receptores Muscarínicos/efectos de los fármacos , Receptores Muscarínicos/metabolismo , Salivación/efectos de los fármacos , Tiadiazoles/farmacocinéticaRESUMEN
Three radiolabeled nicotinic receptor agonists were examined for their binding characteristics and for inhibition by cholinergic compounds in order to distinguish possible differential affinities for subtypes of neuronal nicotinic acetylcholine receptors. KD and Bmax values for [3H]cytisine, [3H]methylcarbamylcholine and [3H]nicotine were determined from Scatchard analysis using an enriched whole-brain membrane fraction from male Sprague-Dawley rats. Respective KD values were 0.15, 1.07 and 0.89 nM while Bmax values were 99, 64 and 115 fmol/mg protein respectively. All three ligands fit a one-site model of receptor-ligand interaction. Concentration-inhibition curves were used to determine Ki values for 16 cholinergic compounds. The rank order of potencies for displacement of the three ligands was: (-)-cytisine > (-)-nicotine > (-)-lobeline = methylcarbamylcholine > 1,1-dimethyl-4-phenylpiperazinium, (+)-nicotine, dihydro-beta-erythroidine, (+/-)-nornicotine > carbachol > arecoline >> oxotremorine, tetrahydroaminoacridine, AF102B >> (-)-cotinine > RS86 = heptylphysostigmine. Correlations of the affinities of these compounds determined with the three ligands were very near to unity. In contrast, there was a negative correlation of affinities for [3H]cytisine compared to affinities for the muscarinic receptor agonist, [3H]oxotremorine-M, and the muscarinic receptor antagonist, [3H]quinuclidinyl benzoate. Using membranes from whole rat brain yields data suggesting that all three nicotinic ligands bind to the same nicotinic acetylcholine receptor subtype, and are unable to distinguish subtypes of neuronal nicotinic acetylcholine receptor at the level examined.
Asunto(s)
Alcaloides/metabolismo , Encéfalo/metabolismo , Carbacol/análogos & derivados , Nicotina/metabolismo , Parasimpaticomiméticos/metabolismo , Receptores Nicotínicos/metabolismo , Animales , Azocinas , Carbacol/metabolismo , Relación Dosis-Respuesta a Droga , Ligandos , Masculino , Quinolizinas , Ratas , Ratas Sprague-DawleyRESUMEN
This study describes the antagonistic properties of himbacine, in comparison with those of pirenzepine, at muscarinic receptors mediating the depolarization of rat superior cervical ganglion, the inhibition of electrically-induced twitch contractions of rabbit vas deferens and the contraction of dog saphenous vein, currently classified as putative muscarinic M1 sites. The affinity of himbacine for the vas deferens site (pA2 8.08) was nearly ten times higher than those for the M1 receptors of rat ganglion and dog saphenous vein (pA2 7.14 and 7.16, respectively); affinity estimates for pirenzepine were similar throughout the different preparations. The present data are consistent with the allocation of ganglion and saphenous vein receptors into the M1 subclass; the profile of the vas deferens site, conversely, appears to be different, and possibly more closely related to that reported for the M4/m4 receptor.
Asunto(s)
Alcaloides/farmacología , Parasimpatolíticos/farmacología , Receptores Muscarínicos/metabolismo , Cloruro de (4-(m-Clorofenilcarbamoiloxi)-2-butinil)trimetilamonio/metabolismo , Cloruro de (4-(m-Clorofenilcarbamoiloxi)-2-butinil)trimetilamonio/farmacología , Acetilcolina/metabolismo , Acetilcolina/farmacología , Alcaloides/metabolismo , Animales , Unión Competitiva , Perros , Femenino , Furanos , Masculino , Muscarina/análogos & derivados , Muscarina/metabolismo , Muscarina/farmacología , Naftalenos , Parasimpatolíticos/metabolismo , Parasimpaticomiméticos/metabolismo , Parasimpaticomiméticos/farmacología , Piperidinas , Pirenzepina/metabolismo , Pirenzepina/farmacología , Conejos , Ratas , Ratas Sprague-Dawley , Receptores Muscarínicos/efectos de los fármacos , Vena Safena/efectos de los fármacos , Vena Safena/metabolismo , Ganglio Cervical Superior/efectos de los fármacos , Ganglio Cervical Superior/metabolismo , Conducto Deferente/efectos de los fármacos , Conducto Deferente/metabolismoRESUMEN
In melanocytes, the biosynthesis of L-dopa derived indole polymer, melanin, is accelerated by tyrosinase and related enzymes. The brown to black pigment is characterized by a stable free-radical property. In humans, a pigment dependent slow onset of ocular actions of ephedrine, atropine, cocaine, pilocarpine and related medications was observed. Extensive accumulation of drugs by melanin appears to be the most important factor governing the long term therapeutic/toxicological activities. Drugs crossing placental circulation are localized in the mouse fetal eye. Thus, drugs exhibit a high binding capacity for melanin containing tissues. Studies on synthetic melanin and melanin granules also indicated a high binding capacity of many therapeutic classes of drugs, including psychotropics. In addition to the liposoluble property of the molecule, there is a definite relationship between chemical structure and the affinity of drugs for melanin. For example, the affinity of chlorpromazine for melanin is higher than that of chlorprothixene. NMR studies, with soluble melanins indicate that there is a steric preference among ephedrine enantiomers. A high binding capacity indicates that more than two molecules of (-)-ephedrine may complex with one indole unit of melanin. Ocular drug development calls for the study of qualitative and quantitative aspects of drug-melanin interaction.
Asunto(s)
Iris/efectos de los fármacos , Melaninas/metabolismo , Animales , Antibacterianos/metabolismo , Antibacterianos/farmacología , Antibacterianos/toxicidad , Encéfalo/metabolismo , Fármacos del Sistema Nervioso Central/metabolismo , Fármacos del Sistema Nervioso Central/farmacología , Fármacos del Sistema Nervioso Central/toxicidad , Gránulos Citoplasmáticos/metabolismo , Interacciones Farmacológicas , Humanos , Iris/metabolismo , Levodopa/metabolismo , Parasimpaticomiméticos/metabolismo , Parasimpaticomiméticos/farmacología , Parasimpaticomiméticos/toxicidad , Unión ProteicaRESUMEN
cis-Methyldioxolane (CD) is a muscarinic receptor agonist. [3H]CD has been used to label a subpopulation of muscarinic receptors described as exhibiting high agonist affinity. Pharmacological evidence suggests that the population of receptors labeled by [3H]CD consists of m2 and/or m4 subtypes; however, no studies have directly addressed the subtype selectivity of [3H]CD. The present study characterizes binding of this ligand to individual human receptor subtypes expressed in transfected Chinese hamster ovary cells. Results indicate that [3H]CD binds with high affinity only to Hm2 receptors but not to all Hm2 receptors. Twenty-eight percent of Hm2 receptors bound [3H]CD with a KD of 3.5 +/- 0.5 nM. Binding was eliminated in the presence of guanosine 5'-O-(3-thiotriphosphate), indicating that the Hm2 receptors labeled by [3H]CD are those that are associated with GDP-bound G protein. Binding of [3H]CD by only a subpopulation of Hm2 receptors is in agreement with data generated from studies of [3H]CD binding in mammalian brain. Because muscarinic receptors have been implicated to play a role in the pathogenesis of both Alzheimer's and Parkinson's disease, as well as the neurotoxicity of organophosphorus compounds, knowledge of the binding specificity of the muscarinic agonist [3H]CD should aid research in these areas.
Asunto(s)
Dioxolanos/metabolismo , Parasimpaticomiméticos/metabolismo , Receptores Muscarínicos/metabolismo , Animales , Unión Competitiva , Células CHO , Membrana Celular/metabolismo , Cricetinae , Guanosina 5'-O-(3-Tiotrifosfato)/farmacología , Cinética , Quinuclidinil Bencilato/metabolismo , Receptores Muscarínicos/análisis , Receptores Muscarínicos/efectos de los fármacosRESUMEN
We have studied the effects of cholinergic agonists on the rates of insulin release and the concentrations of diacylglycerol (DAG) and intracellular free Ca2+ ([Ca2+]i) in the beta-cell line MIN6. Insulin secretion was stimulated by glucose, by glibenclamide and by bombesin. In the presence of glucose, both acetylcholine (ACh) and carbachol (CCh) produced a sustained increase in the rate of insulin release which was blocked by EGTA or verapamil. The DAG content of MIN6 beta-cells was not affected by glucose. Both CCh and ACh evoked an increase in DAG which was maximal after 5 min and returned to basal after 30 min; EGTA abolished the cholinergic-induced increase in DAG. ACh caused a transient rise in [Ca2+]i which was abolished by omission of Ca2+ or by addition of devapamil. Thus, cholinergic stimulation of beta-cell insulin release is associated with changes in both [Ca2+]i and DAG. The latter change persists longer than the former and activation of protein kinase C and sensitization of the secretory process to Ca2+ may underlie the prolonged effects of cholinergic agonists on insulin release. However, a secretory response to CCh was still evident after both [Ca2+]i and DAG had returned to control values suggesting that additional mechanisms may be involved.
Asunto(s)
Calcio/metabolismo , Diglicéridos/metabolismo , Insulina/metabolismo , Islotes Pancreáticos/metabolismo , Muscarina/antagonistas & inhibidores , Parasimpaticomiméticos/metabolismo , Acetilcolina/farmacología , Animales , Bombesina/farmacología , Carbacol/farmacología , Línea Celular , Glucosa/farmacología , Secreción de Insulina , Islotes Pancreáticos/efectos de los fármacos , Muscarina/metabolismo , Factores de TiempoRESUMEN
Heterologous desensitization is a term that indicates that exposure of a cell to an agonist attenuates the response of that cell to other agonists. We examined heterologous desensitization of muscarinic cholinergic receptors of pancreatic acini and characterized mechanisms that might be responsible for desensitization. Muscarinic cholinergic receptor binding was measured by using N-[3H]methscopolamine bromide ([3H]NMS). N-Methscopolamine bromide (NMS), a receptor antagonist, bound to a single class of receptors with an affinity of 0.22 +/- 0.04 nM and a capacity of 61.5 +/- 5.1 fmol/mg of protein. These parameters of NMS binding sites were not altered by an addition of cholecystokinin (CCK) octapeptide, CCK-JMV-180, vasoactive intestinal peptide, 8-bromo-cAMP, 4-bromo-A23187, thapsigargin, or 12-O-tetradecanoylphorbol-13-acetate (TPA). Analysis of competitive inhibition curve of [3H] NMS binding by carbachol showed apparently two classes of carbachol binding sites with high affinity (38.6%) and low affinity (61.4%). Simultaneous incubation of carbachol with CCK or TPA increased the relative affinity of [3H]NMS binding, and the competitive inhibition curves showed a single class of carbachol binding site. L-364,718 blocked the effect of CCK, and staurosporine blocked the effects of TPA and partially blocked the effect of CCK. CCK-JMV-180, vasoactive intestinal peptide, 8-bromo-cAMP, 4-bromo-A23187, and thapsigargin had no effects on the competitive binding. Second, the carbachol-induced sequestration of the receptors was examined. Incubation of acini with carbachol resulted in a decrease of [3H] NMS binding sites, and the addition of CCK or TPA caused an inhibition of the carbachol-induced disappearance of [3H]NMS binding sites. Finally, studies that examined the biological response of the acinar cells showed that biphasic amylase release in response to carbachol was completely suppressed by 10 nM CCK for entire range of carbachol. Taken together, these results suggest that the effect of CCK on carbachol-induced sequestration is important for the alteration of the apparent affinity of carbachol binding sites and the biological response of acinar cells to carbachol. Further, the results suggest that another factor that induces uncoupling of receptor from effector might be involved in agonist-regulated desensitization. The results, that CCK-JMV-180 or other agonists that activate the adenylate cyclase pathway did not exert these effects of CCK, suggest that protein kinase C may be one of the key factors involved in heterologous desensitization by CCK on the carbachol binding sites and the suppression of carbachol-induced amylase release.
Asunto(s)
Páncreas/metabolismo , Parasimpaticomiméticos/metabolismo , Receptores Muscarínicos/metabolismo , Derivados de Escopolamina/metabolismo , Amilasas/metabolismo , Animales , Unión Competitiva , Carbacol/farmacología , Colecistoquinina/farmacología , Relación Dosis-Respuesta a Droga , Técnicas In Vitro , Inositol 1,4,5-Trifosfato/metabolismo , Cinética , Masculino , Antagonistas Muscarínicos , N-Metilescopolamina , Parasimpaticomiméticos/farmacología , Ratas , Ratas Sprague-Dawley , Receptores Muscarínicos/efectos de los fármacos , Acetato de Tetradecanoilforbol/farmacologíaRESUMEN
Some compounds that inhibit acetylcholinesterase (AChE) activity compete directly with quinuclidinyl benzilate (QNB) binding, a muscarinic antagonist which binds to all subtypes equally, and with cis-methyldioxolane (CD), an agonist that binds with high affinity to the M2 subtype of muscarinic receptors. The relationship between inhibition of AChE activity and the capability to affect muscarinic receptors directly has not been systematically explored. The interaction of eight organophosphates with muscarinic receptors was compared to their ability to inhibit AChE activity in vitro in tissue homogenates from rat hippocampus and frontal cortex, two cholinergically enriched areas of the brain. Of the compounds tested only echothiophate competed for [3H]QNB binding and only at concentrations greater than 100 microM. The anticholinesterase compounds were also tested for their ability to compete with a muscarinic receptor agonist, [3H]CD, which binds with high affinity (approximate KD = 3.5 nM) to 10 and 3% of the muscarinic receptors in the frontal cortex and hippocampus, respectively. The anticholinesterase compounds inhibited high-affinity [3H]CD binding up to 80% and the effects were similar in both tissues. Echothiophate and DFP were potent inhibitors of [3H]CD binding, as were the active "oxon" forms of parathion, malathion, and disulfoton. The parent "thio" forms of these insecticides, however, were much less effective in competing for [3H]CD binding. A similar pattern of potency was observed for the inhibition of brain AChE activity. A strong correlation was found between the ability of a compound to inhibit AChE activity and the ability to compete with [3H]CD binding. These data suggest that the biological effects of cholinesterase-inhibiting compounds may be due to more than their ability to inhibit AChE.